Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03543085
Other study ID # PT1710001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 12, 2018
Est. completion date October 23, 2018

Study information

Verified date September 2021
Source GiMer Medical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultra-high frequency (500 KHz) spinal cord stimulation in patients with chronic back pain or lower limb pain.


Description:

This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultra-high frequency (500 KHz) spinal cord stimulation in patients with chronic back pain or lower limb pain. The trial length is 14 days. Patients will be given ultrahigh frequency pulse stimulation, up to 3 times in every 24 hours, and VAS will be obtained at least once a day. Compared to previous study conducted last year, patient can now have two lead implant sites for different pain locations. The electrode implantation site will be epidural space instead of Dorsal Root Ganglion (DRG).


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date October 23, 2018
Est. primary completion date October 23, 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age ?20 and ?75 2. Have a symptom of back or lower limb pain with a diagnosis related to spinal lesion, herniated disc, nerve injury, stenosis, failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS) or ischemic lower limb pain and have pain history of >6 months. 3. Have an average pain score >5 by Visual Analogue Scale (VAS) on inclusion. 4. Has failed to achieve adequate pain relief from prior pharmacologic treatments. 5. In the judgement of the investigator, the subject is an appropriate candidate for the trial procedure. 6. The subject is willing and able to comply with the procedure and requirements of this trial. 7. The participant is able to understand and provide informed consent, and has signed their written informed consent in accordance with Institutional Review Board (IRB) requirements. Exclusion Criteria: 1. Have evidence of a mental or psychological condition that affects pain perception and has difficulty/disability performing objective pain assessment, or have previously failed mental or psychological assessments administered by a psychiatrist that may be deemed to indicate the subject's lack of suitability for participation in this study. 2. Subject has exhibited unstable pain condition within the past 30 days as interviewed by Investigator. 3. Be on anticoagulant medication with International Normalized Ratio (INR) >1.5 or platelet count less than 100,000/µL, peripheral vascular diseases (PVDs), visceral pain or uncontrolled Diabetes mellitus (DM). 4. Has had corticosteroid therapy at an intended site of stimulation within the past 30 days. 5. Pain medication(s) dosages(s) are not stable for at least 30 days at investigator's discretion. 6. Currently has an active implantable device including International Classification of Diseases (ICD), pacemaker, spinal cord stimulator or intrathecal drug pump or subject requires magnetic resonance imaging (MRIs) or diathermy. 7. Have a current diagnosis of cancer with active symptoms. 8. Have a known terminal illness with life expectancy less than one year. 9. Have a systematic or local infection, which may increase study risk. 10. Currently has an indwelling device that may pose an increased risk of infection. 11. Be pregnant or breast feeding. 12. Have a medical history of drug or alcohol addiction within the past 2 years. 13. Participation in any investigational study in the last 30 days or current enrollment in any trial. 14. Be currently involved in an injury claim law suit or medically related litigation, including workers compensation. 15. Be a prisoner.

Study Design


Intervention

Device:
GiMer Medical MN 1000 External Stimulator
Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.

Locations

Country Name City State
Taiwan China Medical University Hospital Taichung

Sponsors (2)

Lead Sponsor Collaborator
GiMer Medical China Medical University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Visual Analog Score From Baseline to Day 14 To assess the analgesic effectiveness of ultra-high frequency spinal cord stimulation, as measured by Visual Analogue Scale (VAS, score min 0 no pain to max 10 worst pain) compared to baseline. 14 days
Primary Record Incidence of Adverse Events To evaluate safety of ultra-high frequency spinal cord stimulation by identifying the incidence rate of adverse events (AEs) and serious adverse events (SAEs) during the trial 14 days
Secondary The Brief Pain Inventory (BPI) The change from baseline in functionality using the BPI evaluations 14 days
Secondary Incidence of Stimulation-induced Paresthesia To determine the presence or absence of stimulation-induced paresthesia. 14 days
Secondary Pain Relief Medication Consumption Amount of pain medication consumption, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and weak opioids, compared to baseline 14 days
Secondary Oswestry Low Back Pain Disability Questionnaire (ODI) The change from baseline in functionality using the ODI evaluations 14 days
See also
  Status Clinical Trial Phase
Completed NCT05452499 - Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae N/A
Recruiting NCT05037682 - Pain and Opioid Management in Older Adults N/A
Completed NCT04080037 - Assessing Opioid Care Practices Using CPV Patient Simulation Modules N/A
Recruiting NCT05382962 - iCanCope With Post-Operative Pain (iCanCope PostOp) N/A
Recruiting NCT04285112 - SPRINT: Signature for Pain Recovery IN Teens
Active, not recruiting NCT04850079 - EHR Precision Drug Treatment in Neonates
Completed NCT03272139 - Interscalene Block Versus Superior Trunk Block Phase 4
Completed NCT03271151 - Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty Phase 4
Completed NCT03886142 - Platelet Rich Plasma Versus Radio Frequency for Chronic Knee Arthritis N/A
Recruiting NCT05761392 - APP-based Precise Management System of Chronic Intractable Pain N/A
Recruiting NCT05877157 - Pain AND Opioids After Surgery
Completed NCT03947749 - Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
Completed NCT03280017 - Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain Phase 4
Recruiting NCT04874038 - Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN) Phase 3
Completed NCT04280796 - Changes in Affective Pain Processing in Human Volunteers N/A
Withdrawn NCT05125978 - Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain Phase 2
Not yet recruiting NCT04328805 - Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome. Phase 4
Completed NCT04976738 - A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain Phase 1/Phase 2
Completed NCT04089618 - Meditation Based Lifestyle Modification in Chronic Pain N/A
Recruiting NCT05699837 - Alpha Entrainment for Pain and Sleep (Extension) N/A